Minimally invasive glaucoma surgery – coming of age

Sng, Chelvin C. A.; Barton, Keith

doi:10.1136/bjophthalmol-2018-313170

Cited by 11 publications

(19 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With regard to the MicroShunt, Baker and coworkers [ 14 ] reported similar rates of endothelial cell loss between the MicroShunt (− 5.2%) and trabeculectomy (− 6.9%) in a large series of surgical patients at 12 months consistent with other reports [ 15 , 25 ]. In a similar fashion, Ibarz-Barberá and coworkers [ 26 ] evaluated the changes in corneal endothelial cell density during the first year following insertion of the implant and reported a 7% loss, which correlated well with the tube–endothelium distance.…”

Section: Safetysupporting

confidence: 80%

Evaluation of a Novel Αb Εxterno MicroShunt for the Treatment of Glaucoma

et al. 2022

View full text Add to dashboard Cite

The surgical management of glaucoma has been revolutionized by the introduction of minimally invasive glaucoma surgery (MIGS). The various MIGS options aim to meaningfully lower intraocular pressure with a better safety profile than traditional glaucoma surgery. The key clinical attributes and the emerging potential of an ab externo MicroShunt (PreserFlo TM ) are reviewed in the context of published evidence and clinical experience. This novel MicroShunt consists of an 8.5-mm-long tube that is implanted in the eye via an ab externo approach enabling aqueous humor drainage into the sub-Tenon's space through the formation of a bleb, similar in appearance to that created by trabeculectomy. The efficacy and safety of this procedure, the concomitant use of antimetabolites, the impact of tube positioning, and its future value in clinical practice are critically reviewed. Recent evidence has demonstrated the MicroShunt to be less effective than traditional filtration surgery, but with a significant improvement in safety. Cumulative data suggest that the new implant provides tangible clinical benefits to selected patients with glaucoma in need of further intraocular pressure (IOP) lowering. Future research should delineate the precise role of this and other MIGS options in the rapidly evolving glaucoma treatment algorithm.

show abstract

Section: Safetysupporting

confidence: 80%

Evaluation of a Novel Αb Εxterno MicroShunt for the Treatment of Glaucoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition, the report may also suggest a modification in the surgical technique of CyPass Microstent implantation, taking care that no rings are visible on anterior chamber angle gonioscopy or photos, which have been used to grade implantation depth in the COMPASS XT. 3,21,22…”

Section: So What Exactly Is the Cypass Ecl Controversy?mentioning

confidence: 99%

“…Which is why the CyPass Micro-Stent gained FDA approval through Premarket Approval (PMA), the most stringent regulatory category for medical devices, while the XEN implant was judged to be “substantially equivalent” to a predicate device, the aqueous shunt implant, and was eligible for FDA registration through the less stringent 510(k) clearance. 3…”

Section: So What Exactly Is the Cypass Ecl Controversy?mentioning

confidence: 99%

See 1 more Smart Citation

Dysgerminoma in Ovarian Dysgenesis with Pregnancy with in vitro Fertilization with Donor Oocyte

Bhartiya¹,

Shaarawy

2017

Journal of Postgraduate Medicine, Education and Research

View full text Add to dashboard Cite

show abstract

“…Most of the available literature identifies micro incisional glaucoma surgery as an emerging option for managing mild to moderate glaucoma 2,3. In this study, the XEN45 implant (micro incisional glaucoma surgery) was used in cases of refractory glaucoma where incisional glaucoma surgeries had previously failed.…”

mentioning

confidence: 99%